<DOC>
	<DOCNO>NCT02492321</DOCNO>
	<brief_summary>This Phase III multi-center , double-masked , vehicle-controlled , randomize , parallel group study evaluate efficacy , safety tolerability EBI-005 compare vehicle give topical ophthalmic solution eye subject moderate severe allergic conjunctivitis ( AC ) three time daily 4 week . Approximately 250 subject approximately 8 center US screen enrol study .</brief_summary>
	<brief_title>A Multi-Center Environmental Study Treatment Moderate Severe Ocular Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Give write informed consent authorization require local law ( e.g. , Protected Health Information waiver ) prior perform study procedure ; Are â‰¥18 year age ; Have positive history ocular allergy ragweed pollen season ; Have sign symptom allergic conjunctivitis eye ; If female childbearing potential , must pregnant lactate Have sign ocular infection ; Have know history alcohol drug abuse ; Have expose investigational drug device within 30 day study ; Have plan surgery ( ocular systemic ) trial period within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>